480 related articles for article (PubMed ID: 25412688)
1. Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease.
Nakouti T; Karagiannis AK; Tziomalos K; Cholongitas E
Curr Vasc Pharmacol; 2015; 13(5):649-57. PubMed ID: 25412688
[TBL] [Abstract][Full Text] [Related]
2. Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Carbone LJ; Angus PW; Yeomans ND
J Gastroenterol Hepatol; 2016 Jan; 31(1):23-31. PubMed ID: 26111358
[TBL] [Abstract][Full Text] [Related]
3. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
Dougherty JA; Guirguis E; Thornby KA
Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083
[TBL] [Abstract][Full Text] [Related]
4. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.
Ohki T; Isogawa A; Toda N; Tagawa K
Clin Drug Investig; 2016 Apr; 36(4):313-9. PubMed ID: 26914659
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus.
Makri E; Kita M; Goulas A; Papaioannidou P; Efstathiadou ZA; Adamidou F; Polyzos SA
Diabetes Metab Syndr; 2020; 14(6):1913-1919. PubMed ID: 33011499
[TBL] [Abstract][Full Text] [Related]
7. The role of oral antidiabetic agents and incretin mimetics in type 2 diabetic patients with non-alcoholic fatty liver disease.
Gouni-Berthold I; Papanas N; Maltezos E
Curr Pharm Des; 2014; 20(22):3705-15. PubMed ID: 24040873
[TBL] [Abstract][Full Text] [Related]
8. Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease.
Li CL; Zhao LJ; Zhou XL; Wu HX; Zhao JJ
J Huazhong Univ Sci Technolog Med Sci; 2015 Jun; 35(3):333-336. PubMed ID: 26072069
[TBL] [Abstract][Full Text] [Related]
9. The effects of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists on cognitive functions in adults with type 2 diabetes mellitus: a systematic review and meta-analysis.
Jin Y; Zhao H; Hou Y; Song G
Acta Diabetol; 2020 Oct; 57(10):1129-1144. PubMed ID: 32300876
[TBL] [Abstract][Full Text] [Related]
10. The role of incretin hormones and glucagon in patients with liver disease.
Junker AE
Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096
[TBL] [Abstract][Full Text] [Related]
11. Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease.
Blaslov K; Bulum T; Zibar K; Duvnjak L
World J Gastroenterol; 2014 Jun; 20(23):7356-65. PubMed ID: 24966606
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.
Wong C; Lee MH; Yaow CYL; Chin YH; Goh XL; Ng CH; Lim AYL; Muthiah MD; Khoo CM
Front Endocrinol (Lausanne); 2021; 12():609110. PubMed ID: 33897616
[TBL] [Abstract][Full Text] [Related]
13. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
Dawwas GK; Smith SM; Park H
Cardiovasc Diabetol; 2018 Jul; 17(1):102. PubMed ID: 30016946
[TBL] [Abstract][Full Text] [Related]
14. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Ranjbar G; Mikhailidis DP; Sahebkar A
Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
[TBL] [Abstract][Full Text] [Related]
15. Incretin-based therapies, glucometabolic health and endovascular inflammation.
Rizzo M; Nikolic D; Banach M; Patti AM; Montalto G; Rizvi AA
Curr Pharm Des; 2014; 20(31):4953-60. PubMed ID: 24320037
[TBL] [Abstract][Full Text] [Related]
16. New anti-diabetic agents for the treatment of non-alcoholic fatty liver disease: a systematic review and network meta-analysis of randomized controlled trials.
Kongmalai T; Srinonprasert V; Anothaisintawee T; Kongmalai P; McKay G; Attia J; Thakkinstian A
Front Endocrinol (Lausanne); 2023; 14():1182037. PubMed ID: 37441498
[TBL] [Abstract][Full Text] [Related]
17. Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease.
Liu Y; Wei R; Hong TP
World J Gastroenterol; 2014 Jul; 20(27):9090-7. PubMed ID: 25083081
[TBL] [Abstract][Full Text] [Related]
18. GLP-1 receptor agonists in NAFLD.
Petit JM; Vergès B
Diabetes Metab; 2017 Apr; 43 Suppl 1():2S28-2S33. PubMed ID: 28431668
[TBL] [Abstract][Full Text] [Related]
19. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.
Drab SR
Pharmacotherapy; 2010 Jun; 30(6):609-24. PubMed ID: 20500049
[TBL] [Abstract][Full Text] [Related]
20. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
